PEPTIDE

Tirzepatide

Dual GIP/GLP-1 receptor agonist with extended half-life (~5 days); enhances insulin secretion, suppresses appetite, and shows additive metabolic effects vs. GLP-1 alone.

BIOGATE · GREEN | POSTERIOR 26.1% | MW 4813.5 | 39AA

SEQUENCE

YXEGTFTSDYSIYLDKQAAKEFVCWLIANGPSSGAPPPS

Modifications: Aib[2]; Aib[13]; ε-Glu-C20 lipid sidechain @ K20; amidated C-terminus

PDA-V1 chain of custody

Outer hash

2-d53ec2f2c53ea9c2f53ef552e53edc22953e5e32853e4502b53e909

Merkle root

9-be8fb6c9ce8fcff9de8fe929ee9002597e8f52098e8f6b399e8f8469ae8f9d9

Inputs

b00129afaf01281cb2012cd5b1012b42ac012363ab0121d0ae01268

TEE attestation

378516-da3885186d358513b4368515473385108e3485122131850d6832850efb

Living Outcome Oracle

± =16.4 ² =46.4 **P(success) = 26.1%**

95% CI [14.1%, 38.1%]

Seven-rule export gate

7 / 7 rules satisfied · audience: researcher · Full attestation set, raw posteriors, all hashes

- Grade A or B citation present on the core claim
- BioGate verdict is GREEN or AMBER (RED/BLACK refused)
- Jurisdiction permits the audience-appropriate use
- RWE summary attached when claim depends on outcome data
- Prediction-outcome pairs disclosed when posterior cited
- No human-use claim beyond cited indications
- COA registry lookup available for any synthesis claim

Citations

GRADE A — 2022 · N Engl J Med

Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1)

Jastreboff AM et al.

DOI 10.1056/NEJMoa2206038